you are here: Home News Cdmo

Cdmo

Syngene: How should one position for it after a disappointing quarter?
Divi’s Lab: Getting ready for peptide opportunity
Navin Fluorine: Revenue visibility getting clearer for the CDMO business
Acutaas Chemicals: Next fiscal to see traction in new businesses
Sai Life Sciences: Getting positioned for complex offerings
Divi’s Lab: Time to take some profit off the table?
Laurus Labs: Is the healthy growth already priced in?
Divi's Labs, Laurus Labs, other pharma shares rise up to 5% as US Senate passes Biosecure Act
What does the new US tariff salvo mean for Indian pharma?
Laurus Labs: Is it time to book profit?
Syngene: How soon can it overcome near-term worries?
How to navigate markets amid Fed’s pause and stagflation risks
Generics drugs are a shrinking market, CDMO hasn’t delivered, hospitals and diagnostics better plays for investors
Divi’s Lab: Capex cycle picks up to meet emerging CDMO demand
What does Trump’s MFN clause mean for the Indian pharma landscape?
Trump’s drug pricing regulation: How does it impact Indian pharma?
Ami Organics: Internal accruals fuel growth capex
Laurus Labs: CDMO-led growth to enhance return ratios
Syngene: Conversion of pilot projects to long-term contracts a big positive
Ami Organics | Strong growth runway for the CDMO business? | Stock of the Day
Ami Organics: CDMO business brightens growth outlook
Akums Drugs signs Rs 1,760 crore CDMO pact with a pharma major for European supply
Divis Lab: GLP-1 opportunity to unfold in the medium term
Senores IPO: A B2B play in pharma generics
Piramal Pharma shares surge 5% after JM Financial recommends Buy, sees 15% topline growth over FY24-27

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Cdmo

Syngene: How should one position for it after a disappointing quarter?

Divi’s Lab: Getting ready for peptide opportunity

Navin Fluorine: Revenue visibility getting clearer for the CDMO business

Acutaas Chemicals: Next fiscal to see traction in new businesses

Sai Life Sciences: Getting positioned for complex offerings

Divi’s Lab: Time to take some profit off the table?

Laurus Labs: Is the healthy growth already priced in?

Divi's Labs, Laurus Labs, other pharma shares rise up to 5% as US Senate passes Biosecure Act

What does the new US tariff salvo mean for Indian pharma?

Laurus Labs: Is it time to book profit?

Syngene: How soon can it overcome near-term worries?

How to navigate markets amid Fed’s pause and stagflation risks

Generics drugs are a shrinking market, CDMO hasn’t delivered, hospitals and diagnostics better plays for investors

Divi’s Lab: Capex cycle picks up to meet emerging CDMO demand

What does Trump’s MFN clause mean for the Indian pharma landscape?

Trump’s drug pricing regulation: How does it impact Indian pharma?

Ami Organics: Internal accruals fuel growth capex

Laurus Labs: CDMO-led growth to enhance return ratios

Syngene: Conversion of pilot projects to long-term contracts a big positive

Ami Organics | Strong growth runway for the CDMO business? | Stock of the Day

Ami Organics: CDMO business brightens growth outlook

Akums Drugs signs Rs 1,760 crore CDMO pact with a pharma major for European supply

Divis Lab: GLP-1 opportunity to unfold in the medium term

Senores IPO: A B2B play in pharma generics

Piramal Pharma shares surge 5% after JM Financial recommends Buy, sees 15% topline growth over FY24-27